S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

bioAffinity Technologies (BIAF) Stock Price, News & Analysis

$1.39
-0.02 (-1.42%)
(As of 05:19 PM ET)
Compare
Today's Range
$1.39
▼
$1.49
50-Day Range
$1.15
▼
$1.69
52-Week Range
$0.95
▼
$3.99
Volume
15,000 shs
Average Volume
352,676 shs
Market Capitalization
$13.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

BIAF stock logo

About bioAffinity Technologies Stock (NASDAQ:BIAF)

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

BIAF Stock Price History

BIAF Stock News Headlines

December 9, 2023 | americanbankingnews.com
Head-To-Head Contrast: bioAffinity Technologies (NASDAQ:BIAF) versus National Research (NASDAQ:NRC)
November 30, 2023 | marketwatch.com
BioAffinity Shares Rise on Addition to Government Pay Schedule
December 11, 2023 | Financial Alphas (Ad)
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
November 30, 2023 | finance.yahoo.com
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
November 15, 2023 | finance.yahoo.com
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
November 14, 2023 | finance.yahoo.com
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
November 6, 2023 | bizjournals.com
SA biotech hire to bolster national expansion
November 6, 2023 | finance.yahoo.com
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
December 11, 2023 | Financial Alphas (Ad)
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
September 7, 2023 | finance.yahoo.com
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
August 16, 2023 | finance.yahoo.com
bioAffinity Technologies Second Quarter 2023 Earnings: US$0.20 loss per share (vs US$0.033 loss in 2Q 2022)
August 11, 2023 | thestreet.com
Bioaffinity Technologies Inc Com
May 15, 2023 | bizjournals.com
SA cancer detection biotech entering critical period
May 15, 2023 | finance.yahoo.com
bioAffinity Technologies Reports First Quarter 2023 Financial Results
May 5, 2023 | fortune.com
How the workforce of the future will be more like an ‘ecosystem’
May 1, 2023 | finance.yahoo.com
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
April 25, 2023 | finance.yahoo.com
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
April 5, 2023 | finance.yahoo.com
bioAffinity Technologies to Ring Nasdaq Closing Bell Today
April 2, 2023 | seekingalpha.com
bioAffinity Technologies GAAP EPS of -$1.81, revenue of $2,500
March 31, 2023 | finance.yahoo.com
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
January 24, 2023 | msn.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.31%
January 24, 2023 | seekingalpha.com
BIAF bioAffinity Technologies, Inc.
January 24, 2023 | finance.yahoo.com
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
January 4, 2023 | finance.yahoo.com
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
December 19, 2022 | finance.yahoo.com
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
December 15, 2022 | finance.yahoo.com
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
November 8, 2022 | finance.yahoo.com
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
See More Headlines
Receive BIAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIAF
CUSIP
N/A
CIK
1712762
Web
www.bioaffinitytech.com
Phone
210-698-5334
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,150,000.00
Net Margins
-2,244.15%
Pretax Margin
-2,240.12%
Return on Equity
-80.82%
Return on Assets
-69.38%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
3.07
Quick Ratio
3.06

Sales & Book Value

Annual Sales
$321,489.00
Price / Sales
43.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
1.11

Miscellaneous

Outstanding Shares
9,502,000
Free Float
5,293,000
Market Cap
$13.97 million
Optionable
Not Optionable
Beta
3.80
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Steven Girgenti (Age 77)
    Founder & Executive Chairman of the Board
    Comp: $93.33k
  • Ms. Maria Zannes J.D. (Age 67)
    Founder, President, CEO & Director
    Comp: $260.81k
  • Dr. Vivienne I. Rebel M.D. (Age 58)
    Ph.D., Executive VP and Chief Medical & Science Officer
    Comp: $238.39k
  • Mr. Michael Dougherty CPA (Age 45)
    M.B.A., VP & CFO
  • Mr. Xavier T. Reveles M.S. (Age 54)
    Chief Operating Officer
  • Mr. Timothy P. Zannes J.D. (Age 70)
    Executive VP, Secretary & General Counsel
  • Ms. Julie Anne Overton
    Director of Communications
  • Mr. Dallas J. Coleman
    National Director of Sales
  • Dr. William Bauta Ph.D.
    Senior Vice President of Therapeutics

Key Competitors

View All Competitors














BIAF Stock Analysis - Frequently Asked Questions

How have BIAF shares performed in 2023?

bioAffinity Technologies' stock was trading at $1.60 on January 1st, 2023. Since then, BIAF stock has decreased by 8.1% and is now trading at $1.47.
View the best growth stocks for 2023 here.

When is bioAffinity Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BIAF earnings forecast.

How were bioAffinity Technologies' earnings last quarter?

bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.30 million for the quarter. bioAffinity Technologies had a negative trailing twelve-month return on equity of 80.82% and a negative net margin of 2,244.15%.

When did bioAffinity Technologies IPO?

(BIAF) raised $8 million in an initial public offering on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager.

How do I buy shares of bioAffinity Technologies?

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BIAF) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -